Description
The invention offers TAT-APOBEC-1 gene therapy for the reduction of serum LDL cholesterol and the associated risk of atherosclerosis. The induction of TAT-APOBEC-1 expression in a limited number of hepatocytes in situ through viral (adenoviral) delivery and its secretion into the local hepatic circulation will result in the local uptake of TAT-APOBEC-1 by liver cells and the induction of Apolioprotein B (apoB) mRNA editing. Liver cells in which editing have been induced by TAT-APOBEC-1 will produce less apoB100 protein and more apoB48 during the process of VLDL assembly and secretion into serum. The novelty of tagging TAT-APOBEC-1 with secretion signals and creating a hepatic mosaic of expression through adenoviral delivery is that the patient
Feb. 1, 2012
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium